Analysts welcome “surprisingly constructive” AstraZeneca US examine knowledge

A bottle of the AstraZeneca vaccine.

Igor Petyx | KONTROLAB | LightRocket via Getty Images

Healthcare analysts welcomed AstraZeneca’s results with the highly anticipated results of the late-stage US trials for its Covid-19 vaccine.

The study, which included more than 30,000 participants in the United States, Peru, and Chile, found the vaccine had an overall effectiveness of 79% in preventing symptomatic Covid and 100% effectiveness in preventing serious illness and hospitalization.

Efficacy was consistent across ages and races, with 80% effectiveness in participants 65 and over. Known as AZD1222 and jointly developed with Oxford University, the vaccine was well tolerated and the independent data security watchdog did not find any security concerns related to the vaccine, the company said Monday.

The data exceeded expectations

In a research note, Jefferies health analyst Peter Welford described the data as “surprisingly positive”.

Adam Barker, Health Analyst at Shore Capital, said, “This is arguably the first study for AZD1222 that has shown convincing efficacy in those 65 years and older.”

This is important as there have been questions about its effectiveness in this age group. Previous studies have been hampered by fewer older participants. In this study, 20% of participants were 65 years of age or older and 60% had comorbidities, which placed them at increased risk of developing serious illnesses.

The test data from Monday critically confirmed the safety profile of the vaccine. Barker emphasized that these data come from a single study using a single dosing regimen and remove the data interpretation complications seen in the past with the AstraZeneca-Oxford surge.

Barker added that the lack of evidence of blood clots in the study was also comforting given recent concerns. “We are not surprised by these data, however, as the evidence of a link between the vaccine and the blood clots was already quite weak.”

AstraZeneca said it will continue to analyze the data and prepare for the primary analysis to be submitted to the U.S. Food and Drug Administration for emergency approval in the coming weeks. The vaccine has already received conditional marketing or emergency marketing authorization in more than 70 countries on six continents.

Dosing regimen a key issue for the FDA

“I can’t understand why the regulator wouldn’t approve this,” Barker wrote, but warned that the detailed data is pending.

A key question for the FDA will be what dosage regimen they will support when they ultimately approve the vaccine.

“This study is based on dosing 4 weeks apart. However, we know that the effectiveness may be higher if you dose with a longer interval (up to 12 weeks) and countries like the UK have this” longer duration between “strategy The doses “used successfully to vaccinate more people quickly,” he relented.

So the question for the FDA is whether they recommend giving the two doses four weeks apart – assuming this was tested in the US study – or including data from the UK and other countries that suggest a longer one Duration is appropriate.

Welford also noted the sub-optimal dosing regimen used in this study. “The study evaluated the 4-week dosing schedule, but we have evidence that the vaccine works better with longer dosing intervals,” he said.

“The primary analysis of the UK, Brazil and South Africa Phase III clinical trials found 62% efficacy when the vaccine was given 4 to 12 weeks apart, but efficacy increased to 82% when the interval was 12 weeks has been extended. “”

In addition to the dosage, analysts are also paying attention to other details about protecting the vaccine from different variants. This is expected to be included in the data packet that will be submitted to the FDA.

Comparing today’s efficacy data with that of some other vaccine manufacturers, Welford warned that Covid-19 variants have become more common since the first vaccine advertisements from Pfizer and Moderna, so the efficacy data is not directly comparable to the efficacy data of various vaccines.

Barker added that the trial results gave the vaccine important validation. “Because of its cost and ease of storage and distribution, AZD1222 was once dubbed the ‘Vaccine for the World’. We think this is a fair label,” he wrote. “Data like this, reported today to be more conclusive about the effectiveness and safety of AZD1222, is certainly cause for celebration.”

AstraZeneca has committed to distribute the vaccine for the duration of the pandemic for no profit. The company’s shares traded 2% higher in London on Monday.

Comments are closed.